We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
-13.06%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$1.87B
AUM Growth
-$516M
Cap. Flow
-$33.5M
Cap. Flow %
-1.79%
Top 10 Hldgs %
48.99%
Holding
144
New
7
Increased
8
Reduced
8
Closed
9

Top Buys

Rank Stock Value
1
SRRK icon
Scholar Rock
SRRK
+$45.3M
2
FATE icon
Fate Therapeutics
FATE
+$16.6M
3
CYTK icon
Cytokinetics
CYTK
+$11.1M
4
SNTI icon
Senti Biosciences Holdings
SNTI
+$4.46M
5
WVE icon
Wave Life Sciences
WVE
+$3.85M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$60.4M
2
PTGX icon
Protagonist Therapeutics
PTGX
+$18.9M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$18M
4
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$15.9M
5
BLU
BELLUS Health Inc.
BLU
+$12.3M

Sector Composition

Rank Sector Weight
1 Healthcare 89.18%
2 Consumer Discretionary 5.28%
3 Financials 0.87%
4 Consumer Staples 0.28%
5 Industrials 0.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SLDB icon
101
Solid Biosciences
SLDB
$792M
$1.85M 0.1%
200,000
– –
GRTS
102
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$1.81M 0.1%
750,000
– –
ORIC icon
103
Oric Pharmaceuticals
ORIC
$1.17B
$1.79M 0.1%
400,000
– –
MREO
104
Mereo BioPharma
MREO
$48.9M
$1.68M 0.09%
1,500,000
– –
CRDF icon
105
Cardiff Oncology
CRDF
$63M
$1.65M 0.09%
750,000
– –
ME
106
DELISTED
23andMe Holding Co
ME
$1.64M 0.09%
33,050
– –
KNTE
107
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$1.58M 0.08%
125,000
– –
CYCN icon
108
Cyclerion Therapeutics
CYCN
$15.2M
$1.52M 0.08%
138,956
– –
AXLA
109
DELISTED
Axcella Health Inc. Common Stock
AXLA
$1.45M 0.08%
28,500
– –
AMLX icon
110
Amylyx Pharmaceuticals
AMLX
$2.19B
$1.45M 0.08%
75,000
– –
XLO icon
111
Xilio Therapeutics
XLO
$59.8M
$1.31M 0.07%
32,143
– –
ARAV
112
DELISTED
Aravive, Inc. Common Stock
ARAV
$1.29M 0.07%
1,311,291
– –
CRIS icon
113
Curis
CRIS
$9.71M
$1.28M 0.07%
3,250
– –
IRWD icon
114
Ironwood Pharmaceuticals
IRWD
$586M
$1.27M 0.07%
110,532
– –
OLMA icon
115
Olema Pharmaceuticals
OLMA
$977M
$1.06M 0.06%
260,500
– –
ORTX
116
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$1.05M 0.06%
180,386
– –
IGMS
117
CALL
DELISTED
IGM Biosciences
IGMS
$902K 0.05%
+50,000
New +$891K
LITS
118
Lite Strategy Inc
LITS
$32.4M
$605K 0.03%
50,000
– –
LVTX
119
DELISTED
LAVA Therapeutics
LVTX
$590K 0.03%
200,000
– –
CDAK
120
DELISTED
Codiak BioSciences, Inc. Common Stock
CDAK
$576K 0.03%
200,000
– –
CRBU icon
121
Caribou Biosciences
CRBU
$146M
$572K 0.03%
105,347
– –
HIPO icon
122
Hippo Holdings
HIPO
$777M
$527K 0.03%
24,000
– –
CRVS icon
123
Corvus Pharmaceuticals
CRVS
$1.1B
$495K 0.03%
500,000
– –
MTCR
124
DELISTED
Metacrine, Inc. Common Stock
MTCR
$462K 0.02%
924,898
– –
INKT icon
125
MiNK Therapeutics
INKT
$51.7M
$408K 0.02%
28,959
– –
2 3 4
5
6

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q2 2022 Portfolio in Review

As of Q2 2022, Artal Group held 144 positions worth $1.87B, down 22% from $2.39B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Artal Group's Q2 2022 filing shows 7 new, 8 increased, 8 reduced and 9 closed positions. Its largest new stake was CinCor Pharma, Inc. Common Stock: 137,010 shares worth $2.58M. The largest sale was argenx, an estimated $60.4M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 91% a quarter earlier, followed by Consumer Discretionary and Financials.

  • Artal Group's largest Q2 2022 buy was CinCor Pharma, Inc. Common Stock: 137,010 shares worth $2.58M.
  • Artal Group added most to Scholar Rock in Q2 2022, an estimated $45.3M increase.
  • Artal Group's biggest Q2 2022 reduction was argenx, cutting an estimated $60.4M.
  • Artal Group fully exited Protagonist Therapeutics in Q2 2022, selling an estimated $18.9M.
  • Artal Group's ten largest holdings make up 49% of its $1.87B portfolio in Q2 2022.
  • Artal Group opened 7 new positions and closed 9 in Q2 2022.
  • Artal Group's portfolio value fell 22% quarter-over-quarter to $1.87B.

Based on Artal Group's 13F filing for Q2 2022, filed 11 Aug 2022.